PMC:7228307 / 656-981 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"20","span":{"begin":284,"end":288},"obj":"Gene"},{"id":"26","span":{"begin":24,"end":30},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Gene:2213"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":31,"end":36},"obj":"Body_part"},{"id":"T6","span":{"begin":46,"end":54},"obj":"Body_part"},{"id":"T7","span":{"begin":189,"end":198},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":24,"end":30},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T10","span":{"begin":31,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T11","span":{"begin":241,"end":244},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T12","span":{"begin":259,"end":260},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T13","span":{"begin":284,"end":286},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":166,"end":180},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_33839"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T5","span":{"begin":31,"end":36},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T1","span":{"begin":166,"end":180},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_33839"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"20","span":{"begin":284,"end":288},"obj":"Gene"},{"id":"26","span":{"begin":24,"end":30},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"pubann:denotes","subj":"20","obj":"Gene:2213"},{"id":"A26","pred":"pubann:denotes","subj":"26","obj":"MESH:D009369"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T5","span":{"begin":31,"end":36},"obj":"Body_part"},{"id":"T6","span":{"begin":46,"end":54},"obj":"Body_part"},{"id":"T7","span":{"begin":189,"end":198},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T1","span":{"begin":76,"end":88},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T1","span":{"begin":24,"end":30},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T1","span":{"begin":24,"end":30},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T1","span":{"begin":76,"end":88},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":76,"end":88},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":24,"end":30},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"or antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may ei"}